论文部分内容阅读
目的探讨Sox2、Ep CAM和Ki-67在三阴乳腺癌原发灶和转移灶中表达的差异及临床意义,为探寻三阴乳腺癌预后标志物和分子治疗的靶点奠定理论基础。方法用免疫组化的方法,检测Sox2、Ep CAM和Ki-67在53例三阴乳腺癌原发灶和相应转移灶中的表达情况,分析表达的差异,进一步探讨其临床意义。结果免疫组化结果显示,Sox2在三阴乳腺癌转移灶中的阳性表达率为84.9%,高于原发灶(67.9%),差异有显著性(P<0.05);三阴乳腺癌转移灶中的Ep CAM和Ki-67高表达率分别为88.7%和92.5%,均高于原发灶(83%和79.2%),但差异无统计学意义(P>0.05)。结论Sox2和Ep CAM可能在三阴乳腺癌浸润、转移过程中发挥了重要的作用,但其确切机制仍待进一步研究。
Objective To investigate the difference and clinical significance of Sox2, Ep CAM and Ki-67 expression in primary breast cancer and metastasis of triple-negative breast cancer, and to lay a theoretical foundation for exploring prognostic markers of triple-negative breast cancer and molecular therapy targets. Methods The expressions of Sox2, Ep CAM and Ki-67 in 53 cases of primary breast cancer and their corresponding metastases were detected by immunohistochemistry. The difference of expression was analyzed and the clinical significance was further explored. Results The positive expression rate of Sox2 in metastatic triple-negative breast cancer was 84.9%, higher than that in primary (67.9%), the difference was significant (P <0.05). The positive rate of Sox2 in metastatic triple-negative breast cancer The high expression rates of Ep CAM and Ki-67 were 88.7% and 92.5% respectively, which were higher than those of the primary tumor (83% and 79.2%, respectively), but the difference was not statistically significant (P> 0.05). Conclusion Sox2 and Ep CAM may play an important role in the invasion and metastasis of triple-negative breast cancer, but the exact mechanism remains to be further studied.